J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.
Wall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setback
Posted in biotech/medical